Cutaneous photosensitivity diseases induced by exogenous agents,☆☆

https://doi.org/10.1016/0190-9622(95)91271-1Get rights and content

Abstract

Cutaneous photosensitivity diseases may be idiopathic, produced by endogenous photosensitizers, or associated with exogenous photosensitizers. Those caused by exogenous agents include phototoxicity, photoallergy, and the exacerbation or induction of systemic disorders in which photosensitivity is a prominent clinical manifestation. Phototoxic disorders have a high incidence, whereas photoallergic reactions are much less frequent. The action spectra for most phototoxins and photoallergens lie in the UVA range. Phototoxic and photoallergic reactions can be distinguished on the basis of pathogenesis, clinical characteristics, diagnosis, and management. Drugs capable of causing phototoxic reactions include psoralens, porphyrins, coal tar, antibiotics, and nonsteroidal antiinflammatory agents. Drugs capable of causing photoallergic reactions include topical antimicrobial agents, fragrances, sunscreens, nonsteroidal antiinflammatory agents, plants, and psychiatric medications. Drug-induced systemic diseases in which photosensitivity is a prominent component include drug-induced lupus erythematosus, porphyria, and pellagra.

References (245)

  • H Torras et al.

    Photo-onycholysis caused by clorazepate dipotassium

    J Am Acad Dermatol

    (1989)
  • CR Daniel et al.

    Nail changes secondary to systemic drugs or ingestants

    J Am Acad Dermatol

    (1984)
  • R Baran et al.

    Drug-induced photo-onycholysis

    J Am Acad Dermatol

    (1987)
  • ML Levy et al.

    Naproxen-induced pseudoporphyria: a distinctive photodermatitis

    J Pediatr

    (1990)
  • EA Leitao et al.

    Bumetanide-induced pseudoporphyria

    J Am Acad Dermatol

    (1990)
  • E Harvey et al.

    Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy

    J Pediatr

    (1992)
  • H Lui et al.

    Photodynamic therapy in dermatology: recent developments

    Dermatol Clin

    (1993)
  • TB Fitzpatrick et al.

    Historical aspects of methoxsalen and other furocoumarins

    J Invest Dermatol

    (1959)
  • CM Jones et al.

    Photodynamic therapy in the treatment of Bowen's disease

    J Am Acad Dermatol

    (1992)
  • P Wolf et al.

    Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid

    J Am Acad Dermatol

    (1993)
  • JC Kennedy et al.

    Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience

    J Photochem Photobiol B

    (1990)
  • T Hasan et al.

    Mechanism of tetracycline phototoxicity

    J Invest Dermatol

    (1984)
  • J Piette et al.

    DNA alterations photosensitized by tetracycline and some of its derivatives

    J Invest Dermatol

    (1986)
  • M Bjellerup et al.

    Photohemolytic potency of tetracyclines

    J Invest Dermatol

    (1985)
  • CR Shea et al.

    Mitochondrial phototoxicity sensitized by doxycycline in cultured human carcinoma cells

    J Invest Dermatol

    (1986)
  • T Meola et al.

    Evaluation of the photosensitive patient

  • CA Elmets

    Cutaneous phototoxicity

  • JH Epstein

    Phototoxicity and photoallergy in man

  • S Epstein

    Chlorpromazine photosensitivity: phototoxic and photoallergic reactions

    Arch Dermatol

    (1968)
  • JE Allen

    Drug-induced photosensitivity

    Clin Pharm

    (1993)
  • VA DeLeo et al.

    Photoallergic contact dermatitis

    Arch Dermatol

    (1992)
  • S Gonçalo et al.

    Pigmented photoallergic contact dermatitis from musk ambrette

    Contact Dermatitis

    (1991)
  • TP Coohill

    Action spectra again?

    Photochem Photobiol

    (1991)
  • IE Kochevar

    Basic principles in photomedicine and photochemistry

  • W Frain-Bell

    Introduction

  • LC Harber et al.

    Photosensitivity diseases related to interior lighting

    Ann N Y Acad Sci

    (1985)
  • RG Freeman et al.

    The action spectrum of photocontact dermatitis

    Arch Dermatol

    (1968)
  • EA Emmet

    Diphenhydramine photoallergy

    Arch Dermatol

    (1974)
  • BL Diffey et al.

    Photobiology of amiodarone: preliminary in vitro and in vivo studies

    Clin Exp Dermatol

    (1984)
  • J Ferguson et al.

    A study of cutaneous photosensitivity induced by amiodarone

    Br J Dermatol

    (1985)
  • EA Emmet

    Phototoxicity from exogenous agents

    Photochem Photobiol

    (1979)
  • DW Owens et al.

    Influence of heat, wind, and humidity on ultraviolet radiation injury

  • PS Song et al.

    Photochemistry and photobiology of psoralens

    Photochem Photobiol

    (1979)
  • JD Spikes

    Photosensitized reactions in mammals

  • IE Kochevar et al.

    Chlorpromazine and protriptyline phototoxicity: photosensitized oxygen-independent red cell hemolysis

    Photochem Photobiol

    (1979)
  • H Mukhtar et al.

    Photoimmunology of photodynamic therapy

  • BW Henderson et al.

    How does photodynamic therapy work?

    Photochem Photobiol

    (1992)
  • S Marcus

    Photodynamic therapy of human cancer: clinical status, potential, and needs

  • AR Oseroff et al.

    Photodynamic therapy (PDT) for treatment of basal cell carcinoma and Bowen's disease: efficacy, mechanisms, and sites of tissue destruction [Abstract]

  • TJ Dougherty et al.

    Cutaneous phototoxic occurrences in patients receiving Photofrin

    Lasers Surg Med

    (1990)
  • Cited by (298)

    • New patterns of cutaneous drug eruptions

      2021, Clinics in Dermatology
    • Nano-phototherapy: Favorable prospects for cancer treatment

      2024, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
    • In silico study of inhibition activity of boceprevir drug against 2019-nCoV main protease

      2024, Zeitschrift fur Naturforschung - Section C Journal of Biosciences
    • Tolerability of St. John's wort - a narrative review

      2023, Zeitschrift fur Phytotherapie
    View all citing articles on Scopus

    The CME articles are made possible through an educational grant from the Dermatological Division, Ortho Pharmaceutical Corporation.

    ☆☆

    Supported by National Institutes of Health grants AR39750, AR32593, and CA48735.

    View full text